3 July 2017 07:00 BST
ASTRAZENECA COMPLETES AGREEMENT
WITH RECORDATI FOR SELOKEN IN EUROPE
AstraZeneca announced today that it has completed* the previously-communicated agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate, respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) medicines in Europe. Metoprolol succinate is a beta-blocker for the control of hypertension, angina and heart failure.
Based on the limited level of ongoing interest that AstraZeneca will retain in the medicines in Europe, the upfront and tiered royalty payments received from Recordati will be reported as Other Operating Income in the Company's financial statements. An upfront payment of $290 million will be accounted for in the second quarter of 2017.
*With the exception of Romania, which is subject to separate closing.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations |
|
|
Esra Erkal-Paler |
UK/Global |
+44 203 749 5638 |
Karen Birmingham |
UK/Global |
+44 203 749 5634 |
Rob Skelding |
UK/Global |
+44 203 749 5821 |
Jacob Lund |
Sweden |
+46 8 553 260 20 |
Michele Meixell |
US |
+1 302 885 2677 |
Investor Relations |
|
|
Thomas Kudsk Larsen |
|
+44 203 749 5712 |
Craig Marks |
Finance, Fixed Income, M&A |
+44 7881 615 764 |
Henry Wheeler |
Oncology |
+44 203 749 5797 |
Mitchell Chan |
Oncology |
+1 240 477 3771 |
Lindsey Trickett |
Cardiovascular & Metabolic Diseases |
+1 240 543 7970 |
Nick Stone |
Respiratory |
+44 203 749 5716 |
Christer Gruvris |
Autoimmunity, Neuroscience & Infection |
+44 203 749 5711 |
US toll free |
|
+1 866 381 7277 |
Adrian Kemp
Company Secretary
AstraZeneca PLC
